Emobot and Hope Therapeutics: What the Partnership Means for IP Clinics

On March 30, 2026, we announced a partnership with Hope Therapeutics, part of NRx Pharmaceuticals (Nasdaq: NRXP), to deploy Emobot passive monitoring across their interventional psychiatry clinic network.

I want to share why this partnership matters — not just as a commercial milestone, but as a signal about where interventional psychiatry is heading.

Why Hope Therapeutics

Hope Therapeutics operates one of the largest IP clinic networks in the US, with a focus on TMS and Spravato programs for treatment-resistant depression. They're not a startup experimenting with digital health — they're an established operator who has seen, firsthand, the problem we're solving.

What convinced them wasn't a pitch deck. It was the data. The r=0.89 correlation with MADRS. The 48-hour relapse early warning. The 80% patient activation rate. And the operational reality that passive monitoring requires nothing from their clinical team beyond a pre-session dashboard review.

What full network deployment means

This isn't a pilot. It's a full deployment across their clinic network — every active TRD patient in their program enrolled in EmoDTx. That scale matters for two reasons.

First, it generates the longitudinal outcome data that the field needs to understand TRD response durability at population scale. Second, it demonstrates that passive monitoring is operationally viable at real clinical volume — not just in research settings.

What it means for other IP clinics

The Hope Therapeutics deployment is a reference case. If you're running a TMS or Spravato program and wondering whether passive monitoring works at clinical scale, this is your answer. We'll be publishing outcome data from the deployment as it accumulates.

If you'd like to see the dashboard before committing, we're happy to walk through a demo — including what the Hope Therapeutics deployment looks like in practice.